Goals of Presentation
|
|
- Cory Stewart
- 5 years ago
- Views:
Transcription
1
2 Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening and current guidelines Review the components of a lung cancer screening program
3 Cancer Screening Fundamental principle: detection of cancer at an early, asymptomatic stage will result in more effective treatment and reduced cancer-specific mortality Ideal screening program Target high risk individuals Use a cost-effective test Exclude individuals without clinically significant abnormalities
4 Lung Cancer Epidemiology 14% of all US cancers Leading cause of cancer-related mortality 1.4 million annual deaths worldwide 160,000 annual deaths in U.S. 27% of all cancer deaths Exceeds deaths due to colorectal, breast, prostate and pancreatic cancers combined Lung cancer among never-smokers would be the 6 th -8 th most common cause of cancer mortality Seigel R, CA J Clinicians 2014; 64: 9
5 Lung Cancer in Wisconsin 4020 estimated cases estimated deaths cases annually seen at Marshfield Clinic
6 Lung Cancer Risk Factors Environmental factors Tobacco smoking 85-90% of lung cancers occur in smokers Relative risk 20-30x Radon 222 exposure Indoor cook stoves Other exposures (e.g. asbestos, silica, arsenic) Diet? Host factors Family history Specific genetic polymorphisms or mutations Chronic lung disease
7 Effect of Smoking Cessation on Lung Cancer Incidence Smoking Status Risk Ratio Men Women Current Smoker Quit < 10 years Quit years Quit years > 30 years 0.10 Never-smoker For women > 20 years Peto R, et al BMJ 2000; 321: 323-9
8 NSCLC Prognosis Stage Frequency 5 Year Survival (%) 0 NA 100 IA IB 55 IIA IIB 40 IIIA IIIB 5-10 IV
9 Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening and current guidelines Review the components of a lung cancer screening program
10 Lung Cancer Screening Until 2010, no evidence existed for a mortality benefit from screening with chest x-ray, lung CT scanning or sputum cytology October 2010 results of the National Lung Screening Trial (NLST) initially announced followed by a full report published online June 29, 2011 and in print August 2011
11 National Lung Screening Trial (NLST) Randomized, controlled trial comparing low dose CT scans (LDCT) to chest radiograph (CXR) annually for 3 years in high risk population Powered to detect 20% reduction in lung cancer- specific mortality 55,434 randomized Marshfield Clinic) Screening conducted at 33 sites in US NLST Research Team, NEJM 2011; 365: 395
12 National Lung Screening Trial (NLST) Eligibility and Exclusions Eligibility Age years 30 pack-years smoking history Former smokers quit 15 years Exclusions Previous lung cancer diagnosis Chest CT within 18 months Hemoptysis Unexplained weight loss >15 lbs. NLST Research Team, NEJM 2011; 365: 395
13 Positive LDCT Screen in NLST Non-calcified nodule > 4 mm (97.6% of positives) Adenopathy Pleural effusion Consolidation, atelectasis
14 NLST Results Screen positivity T0 27.3% T1 27.9% T2 16.8% False positivity 96.4% of positive screens are false + Of all LDCTs, 23.3% false +
15 NLST Results With median follow-up 6.5 years, cancer deaths LDCT 247 CXR % mortality reduction 13% excess of lung cancers in LDCT arm possible overdiagnosis 63% of cancers in LDCT arm stage IA-IB Number needed to screen to prevent 1 death=320 NLST Research Team, NEJM 2011; 365: 395
16 NLST Lung Cancer Mortality?Overdiagnosis NLST Research Team, NEJM 2011; 365: 395
17 Complications in NLST Complications a LDCT (%) CXR (%) Total Patients without lung ca Patient with lung ca Death within 60 days of procedure a Major: respiratory failure, anaphylaxis, cardiac arrest, BP fistula, MI, CVA, hemothorax, empyema, thromboembolism, brachial plexopathy Intermediate: blood loss, fever, infection, pain, arrhythmia, vocal cord injury or paralysis, pneumothorax Minor: allergic reaction, bronchospasm, vasovagal reaction, subcutaneous emphysema, ileus
18 Lung Cancer Screening NLST cited as 1 of 10 most important advances in 2011 Estimated potential to save 30,000 lives annually in US
19 Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening and current guidelines Review the components of a lung cancer screening program
20 LDCT Lung Cancer Screening Pros and Cons PROS Reduced lung cancer mortality Teachable moment for smoking cessation CONS False + LDCT, resulting in: Anxiety, stress Unnecessary testing Overdiagnosis Morbidity and mortality from diagnostic evaluations Radiation exposure and risk of 2 nd malignancy False examinations Cost to healthcare system
21 Overdiagnosis Detection of cancer (usually through screening) that would not otherwise have become apparent during the individual s lifetime Results in unnecessary treatment, morbidity, cost, anxiety and labeling of patient with diagnosis Occurs in all forms of cancer screening
22 Overdiagnosis in LDCT Screening Estimates of overdiagnosis rate NLST 18-22% (comparison of screened to control arm) COSMOS 25% (based on volume doubling time) Implications These are probably maximum estimates based on 3-7 years follow-up Overdiagnosed cancers predominantly indolent A high proportion of overdiagnosed lung cancers are broncho-alveolar (lepidic growth) carcinomas
23 LDCT Screening Radiation Risk Radiation exposure LDCT Screening exam (non-contrast) 1.5 msv (comparable to 6 months normal background radiation) Diagnostic chest CT 7 msv (2 years background radiation) Radiation-induced lung cancer risk Individual % estimated risk Population estimates 1.8% increase in lung cancers, if 50% of eligible patients are screened over 25 years (Brenner DJ) 3-6 cases/100,000 screened patients over years (International Commission on Radiologic Protection) fatal lung cancers/100,000 screened (Italung-CT Trial) Conclusion: there is some increased individual risk and greater population risk, but benefits of screening outweigh this risk
24 LDCT Screening Recommendations 2014 Organization 1 0 Population Other Considerations USPSTF (2013) AATS (2012) ASCO-ACCP (2012) ACS (2013) NCCN (2011) Age a + >30 packyears; quit <15 years Age >30 packyears Age >30 packyears; quit <15 years c Age >30 packyears; quit <15 years c Age >30 packyears; quit <15 years c NA Age> pack-years + additional risk factor b ; or lung ca survivor >5 years NA NA Age > pack years + additional risk factor d a Based on modeling predictions b COPD, environmental or occupation exposure, prior cancer, thoracic RT, genetic or family history c NLST eligibility criteria d cancer history, lung disease, family history of lung ca, radon or occupational exposure
25 USPSTF Recommendations
26 Lung Cancer Screening Coverage ACA requires private insurance coverage without costsharing for USPSTF A or B recommendations CMS coverage decisions are independent of ACA requirement
27 LDCT Lung Cancer Screening CMS (Medicare) Coverage Medicare Evidence Development and Advisory Committee (MEDCAC) recommended against approval , based on Complications of screening Radiation exposure Uncertainty about benefit of screening in Medicare-aged population
28
29 NLST Results by Age Parameter 65+ <65 PPV 4.9% 3.0% Screen-detected cancer 394/ /10 4 Lung cancer resection Overall 73.2% 75.6 Stage I 93.0% 96.9% Surgical mortality 1.0% 1.8% False % 22.0% Invasive procedures after false+ 3.3% 2.7% 5-year all cause survival 55.1% 64.1% NNTS to prevent 1 death Pinsky PF, et al Ann Int Med 2014; 161:
30 NLST Results by Age LDCT screening is more efficient in the 65+ age group (but no data on patients >76 years old at time of screening) Higher false + rate in 65+ group Higher rate of invasive diagnostic procedures in 65+ group, but equivalent ratio of invasive procedures to lung cancer deaths averted (5.9) in both age groups Both age groups had comparably high rates of surgical resection and low surgical mortality; this may in part reflect a healthy volunteer effect Pinsky PF, et al Ann Int Med 2014; 161:
31 NLST and Age Take Home Message... LDCT screening seems to involve similar tradeoffs for persons who meet NLST eligibility criteria in both the older and younger age groups. Until there is new and direct evidence to the contrary, it does not seem reasonable to exclude persons aged 65 to 74 years from access to screening. Gould MK, Ann Int Med 2014; 161: 672-3
32 LDCT Lung Cancer Screening CMS (Medicare) Coverage CMS approval evidence is sufficient to add a lung cancer screening counseling and shared decision making visit, and for appropriate beneficiaries, annual screening for lung cancer with low dose computed tomography (LDCT), as an additional preventive service benefit under the Medicare program...
33 LDCT Screening Cost-Effectiveness Incremental cost-effectiveness ratios $52,000/life-year gained $81,000/quality life-year gained Higher cost-effectiveness Women Higher risk individuals Current vs former smokers Older age Estimates vary with assumptions Adding smoking cessation program improves costeffectiveness estimates Black WC, et al NEJM 2014; 371:
34 Standard fee $250 LDCT Screening Cost Marshfield Clinic Covered by WI Medicare and Medicaid Commercial coverage variable Much of the total screening-related cost results from diagnostic evaluation of positive LDCTs
35 How Can We Improve Efficiency and Effectiveness of LDCT Screening? Improve selection criteria by refined risk prediction models PLCO M2012 (Tammemagi MC, et al NEJM 2013) Liverpool Lung Project Risk Model (Raji OY, et al Ann Int Med 2012) Use of modified criteria for positive scans e.g. Lung- RADS (Pinsky PF, Ann Int Med 2015)
36 How Can We Improve Efficiency and Effectiveness of LDCT Screening? Improve selection criteria by refined risk prediction models PLCO M2012 (Tammemagi MC, et al NEJM 2013) Liverpool Lung Project Risk Model (Raji OY, et al Ann Int Med 2012) Use of modified criteria for positive scans e.g. Lung- RADS (Pinsky PF, Ann Int Med 2015)
37 Targeting LDCT Screening by Risk of Lung Cancer Death 5 year lung cancer death risk quintiles Q5 > 2.00% Q % Q % Q % Q % Kovalchik SA, et al NEJM 2013; 369:
38
39 PLCO M2012 Modified logistic regression prediction model for lung cancer risk Model variables: age, race, education, BMI, COPD, history of cancer, family history of lung cancer, smoking status, smoking intensity, duration of smoking, smoking quit time
40 Selection Criteria NLST vs PLCO M2012 Tammemagi MC, et al NEJM 2013; 368:
41 How Can We Improve Efficiency and Effectiveness of LDCT Screening? Improve selection criteria by refined risk prediction models PLCO M2012 (Tammemagi MC, et al NEJM 2013) Liverpool Lung Project Risk Model (Raji OY, et al Ann Int Med 2012) Use of modified criteria for scan assessment e.g. Lung- RADS (Pinsky PF, Ann Int Med 2015)
42 Lung-RADS Nodule Surveillance
43 Application of Lung-RADS to NLST Parameter Baseline (%) After Baseline (%) Lung- Rads NLST Lung-Rads NLST Sensitivity False PPV NPV Retrospective application of Lung- RADS criteria to NLST 75% reduction in false + Uncertain impact of sensitivity on lung cancer mortality Pinsky PF, et al Ann Int Med 2015
44 Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening Review the components of a lung cancer screening program
45 Implementation of LDCT Screening Program American College of Chest Physicians and American Thoracic Society issued policy statement October 2014 Nine essential components of LDCT screening program Mazzone PJ, et al Chest 2014
46 ACCP/ATS Principles for High-Quality Lung Cancer Screening Programs Use of existing guidelines such as USPSTF to determine who to screen, how frequently and how long Use of ACR-STR specifications for performance of LDCT Use of consistent definition of positive LDCT exam Use of structured reporting system, such as Lung-RADS Availability of multi-disciplinary clinical team for management of lung nodules and lung cancers Use of evidence-based nodule management algorithms Mazzone PJ, et al Chest 2014
47 ACCP/ATS Principles for High-Quality Lung Cancer Screening Programs-2 Inclusion of smoking cessation program with screening Standardized communication to referring provider and patient Patient and provider education programs are part of screening program Data collection (nodules, cancers, complications) Support for research into all aspects of lung cancer screening Development of multi-society/multi-disciplinary oversight and credentialing body Mazzone PJ, et al Chest 2014
48 LDCT Screening Many Questions Remain Who should be screened (what are optimal selection criteria)? How frequently should screening occur? When should screening begin, and how long should screening continue? What are the health risks of LDCT screening, including radiation exposure? Can LDCT be combined with biomarker studies to improve effectiveness?
49 Future Role of Biomarkers Currently no established role in screening In the future will likely be helpful Risk models Screening
50 Summary Lung cancer is the #1 cause of cancer mortality Data from NLST demonstrate a 20% mortality reduction from LDCT screening of high-risk population In appropriate populations, the benefits of screening outweigh the harms LDCT screening now covered by CMS and most insurers Implementation of an effective screening program is complex and requires multi-disciplinary collaboration, organization, data collection, quality improvement There remain many unanswered questions that can be addressed by continued data collection and research WCC should support and monitor development of high-quality lung cancer screening programs in Wisconsin
51 Thank You For Your Attention Questions?
Disclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures
Updates in Lung Cancer Screening Disclosures No Financial Disclosures Neil Trivedi, MD Associate Professor of Clinical Medicine SF VAMC Pulmonary and Critical Care Director, Bronchoscopy & Interventional
More informationLung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
More informationLung Cancer Screening: Benefits and limitations to its Implementation
Lung Cancer Screening: Benefits and limitations to its Implementation Rolando Sanchez, MD Clinical Assistant Professor Pulmonary-Critical Care Medicine University of Iowa Lung cancer - Epidemiology Cancer
More informationScreening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
More informationChristine Argento, MD Interventional Pulmonology Emory University
Christine Argento, MD Interventional Pulmonology Emory University Outline Lung Cancer Statistics Prior Studies for Lung Cancer Screening NLST Studies Following NLST Future Directions Lung Cancer American
More informationLDCT Screening. Steven Kirtland, MD. Virginia Mason Medical Center February 27, 2015
LDCT Screening Steven Kirtland, MD Virginia Mason Medical Center February 27, 2015 2 Disclosures 4 5 Cancer Screening Mrs H 64yo 50 pk year smoker Lung Cancer Epidemiology Leading Cause of Cancer Death
More informationLUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University Objective LDCT lung cancer screening (LCS) Potential Benefits & Harms Recommendation of
More informationLUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
More informationSCREENING FOR EARLY LUNG CANCER. Pang Yong Kek
SCREENING FOR EARLY LUNG CANCER Pang Yong Kek Lecture Outline Why performing screening? How to improve early detection? Benefits and Risks of screening Challenges in screening Conclusion Why Performing
More informationCurrent Approach to Screening for Lung Cancer. James R Jett M.D.
Current Approach to Screening for Lung Cancer James R Jett M.D. Potential Conflicts of Interest I am Chief Medical Officer for Oncimmune Ltd (Biomarkers of Cancer) Co-Editor of Lung Cancer Section of UP-TO-DATE
More informationLUNG CANCER SCREENING
LUNG CANCER SCREENING Christopher Lettieri MD, FACP, FCCP, FAASM Pulmonary/Critical Care Consultant to the Surgeon General Professor of Medicine Walter Reed National Military Medical Center American College
More informationLung Cancer and CT Screening
Lung Cancer and CT Screening Samer Kanaan, MD February 17 th, 2012 Goals Understand the Societal impact of Lung Cancer Identify Risk Factors for Lung Cancer List Diagnostic Tests Available for Lung Cancer
More informationLung Cancer Screening In High Risk Populations:
Lung Cancer Screening In High Risk Populations: Michael Jaklitsch, M.D. Co-Chair of AATS Task Force on Lung Cancer Screening and Surveillance From the Brigham and Women s Hospital Harvard Medical School.
More informationScreening for Lung Cancer - State of the Art
Screening for Lung Cancer - State of the Art Rohit Kumar, MD Assistant Professor of Medicine Fox Chase Cancer Center Temple University School of Medicine Philadelphia, PA Objectives Review current evidence
More informationThe Challenge of Cancer Screening Part One Prostate Cancer and Lung Cancer Screening
The Challenge of Cancer Screening Part One Prostate Cancer and Lung Cancer Screening The Challenge of Cancer Screening Part One Prostate Cancer and Lung Cancer Screening By Marsha Fountain, RN, MSN The
More informationLung Cancer screening :
Lung Cancer screening : Pro-Contra SAMO interdisciplinary workshop on chest tumors 27 and 28 january 2017 Prof L.P.Nicod Sevice de pneumologie CHUV-Lausanne -CH Lung Cancer How big is the problem? Epidemiology
More informationLUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018
LUNG CANCER: LDCT Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, 2018 DISCLOSURES 2 NONE 1 OBJECTIVES 3 Rationale and evidence for LDCT for lung cancer screening Review
More informationDISCLOSURE. Lung Cancer Screening: The End of the Beginning. Learning Objectives. Relevant Financial Relationship(s) Off Label Usage
Peninsula Regional Medical Center 12 th Annual Lung Cancer Conference March 9, 2017 Lung Cancer Screening: The End of the Beginning David E. Midthun M.D. Professor of Medicine College of Medicine, Mayo
More informationLung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
More informationExample of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
More informationCLINICAL GUIDELINES. Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P.
CLINICAL GUIDELINES Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P. 3/14/2015 Introduction: The purpose of a lung-cancer screening program is to detect
More informationPage 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
More informationCT screening for lung cancer. Should it be done in the Indian context?
CT screening for lung cancer Should it be done in the Indian context? Wilson and Jungner screening criteria 1. The condition sought should be an important health problem. 2. There should be an accepted
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationRichard M. Hoffman, MD, MPH University of Iowa Carver College of Medicine Holden Comprehensive Cancer Center
Richard M. Hoffman, MD, MPH University of Iowa Carver College of Medicine Holden Comprehensive Cancer Center Consultant, Healthwise, developing cancer screening decision support tools Consultant, Agency
More informationWhat to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
More informationLUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS?
LUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS? DAVID O. WILSON, MD, MHP DIRECTOR GEORGIA COOPER MEMORIAL LUNG CANCER RESEARCH REGISTRY UNIVERSITY OF PITTSBURGH
More informationLow-Dose CT Cancer Screening Program
Low-Dose CT Cancer Screening Program 1 History of Low-Dose CT Screening In 2011, the National Lung Screening Trial (NLST) was the first trial that provided evidence based support that Low-Dose CT (LDCT)
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationNone
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
More informationLung Cancer Screening: Now What?
Lung Cancer Screening: Now What? Gerold Bepler, M.D., Ph.D. Director, President & CEO Michigan Cancer Consortium, 2013 Annual Meeting, Lansing, MI, 11/20/13 Lung Cancer #1 Cause of Cancer Death for & *
More informationLung Cancer Screening Benefits, Risks & Challenges
Lung Cancer Screening Benefits, Risks & Challenges Polly Sather, APRN Yale Lung Screening and Nodule Program (Yale Lung SCAN) A Multidisciplinary Comprehensive Initiative Yale Cancer Center Thoracic Oncology
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationLung Cancer Screening
Lung Cancer Screening Steven Leh, MD, FCCP Diplomat of the American Association for Bronchology and Interventional Pulmonology Aurora Medical Group Pulmonary and Sleep Medicine February 10, 2018 Disclosures
More informationNew Advances in Lung Cancer
New Advances in Lung Cancer Douglas E. Wood, MD, FACS, FRCSEd (ad hom) Professor and Chief Division of Cardiothoracic Surgery Vice-Chair, Department of Surgery Endowed Chair in Lung Cancer Research University
More informationLung Cancer Screening: Current Status
Lung Cancer Screening: Current Status I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of investigational or off-label use of a product
More informationLung Cancer Screening. Eric S. Papierniak, DO NF/SG VHA UF Health
Lung Cancer Screening Eric S. Papierniak, DO NF/SG VHA UF Health Overview Background Supporting evidence Guidelines Practical considerations Patient selection What to do with abnormal results Billing/coding
More informationLung Cancer Screening: Radiologic and Clinical Implications. Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill
Lung Cancer Screening: Radiologic and Clinical Implications Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill Nothing to disclose Objectives In context of NLST: Review Imaging Techniques
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationLung Cancer Screening
Lung Cancer Screening Preston Wright, DO University of Kansas School of Medicine- Wichita Family Medicine Residency at Via Christi Hospitals 1 Objectives Identify patients who need screened for lung cancer
More informationCriteria USPSTF CMS. Frequency Annual screening Annual screening. No signs or symptoms of lung cancer
Lung Cancer Screening Guidelines with low- dose computed tomography (LDCT): USPSTF and CMS February 6, 2015 Kentucky Cancer Consortium and Kentucky LEADS Component 3 Jennifer Redmond Knight, DrPH, jredknight@kycancerc.org
More informationPage 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
More informationSelected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice
Cancer Screening Using Best Evidence to Guide Practice Judith M.E. Walsh, MD, MH Division of General Internal Medicine Women s Health Center of Excellence University of California, San Francisco Selected
More informationA Comprehensive Cancer Center Designated by the National Cancer Institute
N C I C C C A Comprehensive Cancer Center Designated by the National Cancer Institute Screening and Early Detection of Lung Cancer: Ready for Practice? David S. Ettinger, MD, FACP, FCCP Alex Grass Professor
More informationPANEL DISCUSSION: SCREENING FOR LUNG CANCER. Anthony D Weaver MD
PANEL DISCUSSION: SCREENING FOR LUNG CANCER Anthony D Weaver MD Disclosures Anthony Weaver has no relationships to disclose. Thank God! A panel of experts! An Equal Opportunity University Objectives 1.
More informationNCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening
444 Original Research NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening Brady J. McKee, MD; Shawn Regis, PhD; Andrea K. Borondy-Kitts, MS, MPH; Jeffrey A. Hashim, MD; Robert J.
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationAmerican Medical Association Journal of Ethics
American Medical Association Journal of Ethics July 2015, Volume 17, Number 7: 601-607 ETHICS CASE Close-Call Screening and Shared Decision Making Commentary by Evelyn Chan, MD, MS Dr. Samuelson is an
More informationObjectives. Why? Why? Background 11/5/ % incurable disease at presentation Locally advanced disease Metastasis. 14% 5 year survival
Objectives Appraise lung cancer screening trials results Review screening guidelines Lung Cancer Screening: Past, Present and Future Chi Wan Koo, MD Koo.chiwan@mayo.edu Discuss recommendations essential
More informationWill CT screening reduce overall lung cancer mortality? Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH
Will CT screening reduce overall lung cancer mortality? Heidi Roberts MD FRCP(C) Heidi Roberts, MD, FRCP(C) Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH Screening - Requirements
More informationAn Update on Lung Cancer Screening Policy and the Role of Quitlines
An Update on Lung Cancer Screening Policy and the Role of Quitlines Robert J. Volk, PhD Vance Rabius, PhD The University of Texas MD Anderson Cancer Center North American Quitline Consortium NAQC Conference
More informationLung Cancer Screening. Ashish Maskey MD Interventional Pulmonology UK Health Care Dec 1 st 2017
Lung Cancer Screening Ashish Maskey MD Interventional Pulmonology UK Health Care Dec 1 st 2017 Nearly one in six American adults currently smoke cigarettes An estimated 40 million adults in the United
More informationPulmonologist s Perspective
Low-dose CT for lung cancer screening Pulmonologist s Perspective Literature Review Kang-Yun Lee, MD PhD Department of Thoracic Medicine Taipei Medical University- Shuang Ho Hospital Taiwan Local vs. Advanced
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationLung Cancer Screening Trials. Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital
Lung Cancer Screening Trials Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital Lung Cancer Screening in Australia Not Funded except as part of a clinical trial Rationale PLCO, ELCAP
More information10/17/16. Lung Cancer Screening. Question 1: Does lung cancer screening make sense? 3rd lung cancer third most prevalent tumor type
Lung Cancer Screening Greg Rogalski Mercy Radiology Group greg@grogo.org Question 1: Does lung cancer screening make sense? 2 Requirements for successful screening process Sufficiently high prevalence
More informationUniversity of Connecticut. University of Connecticut Graduate School
University of Connecticut OpenCommons@UConn Master's Theses University of Connecticut Graduate School 5-7-2016 A Retrospective Study Assessing the Predictive Performance of a Lung Cancer Screening Risk
More informationA Summary from the 2013World Conference on Lung Cancer Sydney, Australia
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia In 2011, the U.S. National Lung Screening Trial (NLST) has demonstrated that low-dose computed tomography (LDCT) screening of high
More informationDOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS
DOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS December 2018 Page 1 of 18 Document Title: Document Ref. Number: DOH Lung Cancer Screening Service Specifications PH/NCD/LCSC/SR/0.9 Version: 0.9 Approval
More informationCT Low Dose Lung Cancer Screening. Part I. Journey to LDCT LCS Program
CT Low Dose Lung Cancer Screening Part I Journey to LDCT LCS Program Paul Johnson, M.S., DABHP, DABR Cleveland Clinic September 26, 2015 Lung Caner is No. 1 In Cancer Related Death In The United States
More informationSHARED DECISION MAKING AND LUNG CANCER SCREENING
SHARED DECISION MAKING AND LUNG CANCER SCREENING DISCLOSURES Cathleen E. Morrow, MD None William C. Black, MD No financial disclosure Co-investigator for NLST Member of the ACR Lung-RADS Screening Registry
More informationScreening for Lung Cancer. Michael S. Nolledo, MD Deborah Heart and Lung Center
Screening for Lung Cancer Michael S. Nolledo, MD Deborah Heart and Lung Center 1 1 Outline Ø Introduction Ø Lung Cancer Screening pre-2010 Ø Lung Cancer Screening today 2 2 Lung Cancer 2011 (Siegel et
More informationFaculty Disclosure. Objectives. Lung Cancer in Kentucky: Improving Patient Outcomes 10/28/16. Lung Cancer Burden in Kentucky
Lung Cancer in Kentucky: Improving Patient Outcomes Faculty Disclosure The presenter and members of the development team do not have any conflicts to report. Celeste T. Worth, MCHES Kentucky Collaborative
More informationCancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide
Cancer Screening 2012 Letting Evidence Be Our Guide Jeffrey A. Tice, MD Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Principles of screening
More informationSHARED DECISION MAKING IN MEDICARE COVERAGE
SHARED DECISION MAKING IN MEDICARE COVERAGE Kate Goodrich, MD MHS Director, Center for Clinical Standards and Quality CMS April 2, 2016 Disclaimer: Views and comments in this presentation are those of
More informationLung Cancer Screening: Evidence and current recommendations
Lung Cancer Screening: Evidence and current recommendations 20 th March 2018 Dr Annette McWilliams Fiona Stanley Hospital University of Western Australia WA Cancer & Palliative Care Network I have no financial
More informationThe National Lung Screening Trial (NLST)
The National Lung Screening Trial (NLST) Pamela Marcus US National Cancer Institute May 21, 2012 Today s talk NLST: an overview Typical challenges in cancer screening RCTs Starting ti a trial in the presence
More informationScreening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
More informationCT Lung Screening Implementation Challenges: State Based Initiatives
CT Lung Screening Implementation Challenges: State Based Initiatives Andrea McKee, MD Chair Radiation Oncology Lahey Hospital and Medical Center Co-Director Rescue Lung, Rescue Life Program Co-Chair Massachusetts
More informationVHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening
VHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening ATS San Francisco 2016 James K. Brown MD 1, Kathryn L. Rice, MD 2 (1) San Francisco VA (2) Minneapolis VAMC Disclosures
More informationScreening for Lung Cancer
Screening for Lung Cancer 15 ΜΑΡΤΙΟΥ 2014 Ioannis Gkiozos Pulmonologist Oncology Unit G P General & Chest Diseases Hospital Sotiria Despite advances in therapy, 5-year survival rates of Lung Cancer Remains
More informationThe complex, intertwined role of patients in research and care
Session 3: The complex, intertwined role of patients in research and care Joseph Chin, MD, MS, Acting Deputy Director, Coverage and Analysis Group, Centers for Medicare & Medicaid Services The complex,
More informationIntroduction and Background
CT Lung Cancer Screening and the Medical Physicist: Background, Findings and Participant Dosimetry Summary of the National Lung Screening Trial (NLST) Randell Kruger, PhD, DABR Medical Physics Section
More informationProfessor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK.
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK. J.K.Field@liv.ac.uk 1.8 million new cases in 2012 Bender Nature Outlook 2014 Probability of survival: ALL participants
More informationEmerging Challenges in Primary Care: Lung Cancer Screening: Who, When, Why Or Why Not? Objectives. Faculty
Emerging Challenges in Primary Care: 2017 Lung Cancer Screening: Who, When, Why Or Why Not? Louis Kuritzky, MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine University
More informationEquity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA
Equity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA Mary Pasquinelli, MS, APRN, FNP-BC Pulmonary and Thoracic Medical Oncology Director,
More informationLung Cancer Screening Who, When, Why
Lung Cancer Screening Who, When, Why Louis Kuritzky, MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine University of Florida, Gainesville (352) 377 3193 Phone/FAX
More informationThe Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
More informationLung cancer Screening
Lung cancer Screening Family Physicians and CancerControl 2018 Alain Tremblay Division of Respiratory Medicine University of Calgary Disclosures BD Inc - Consultant / Medical Device development Olympus
More informationLung Cancer Screening
Lung Cancer Screening Ravi Salgia, M.D., Ph.D. Professor and Chair Medical Oncology and Therapeutics Research City of Hope Nothing to disclose Disclosure Lung Cancer 2016 >200,000 cases projected >160,000
More informationCancer Screenings and Early Diagnostics
Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6
More informationEvidence-based Cancer Screening & Surveillance
Oncology for Scientists Spring 2014 Evidence-based Cancer Screening & Surveillance Martin C. Mahoney, MD, PhD, FAAFP Departments of Medicine & Health Behavior /Oncology_Feb 2014.ppt 1 Objectives: Principles
More informationIEHP UM Subcommittee Approved Authorization Guidelines CT Screening (Low Dose) for Lung Cancer
CT Screening (Low Dose) for Lung Cancer Policy: There is currently adequate evidence that using low dose computed tomography (LDCT) to screen asymptomatic individuals who are at risk for lung cancer improves
More informationMEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) FOR LUNG CANCER SCREENING. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED CANCER SCREENING 05/18/05, 03/16/06, 12/21/06, 08/16/07, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria
More informationEarly Detection of Lung Cancer. Amsterdam March 5 th 2010
Early Detection of Lung Cancer Amsterdam March 5 th 2010 Rob J van Klaveren, MD, PhD Dept. of Pulmonology Erasmus MC Rotterdam, the Netherlands Early Detection and Screening - Questions to be addressed
More informationPage 1. Controversies in Cancer Prevention and Screening. Disclosures. Screening. Principles of Screening. I have no conflicts of interest
Controversies in Cancer Prevention and Screening Disclosures Using the Best Evidence in 2015 I have no conflicts of interest Judith M.E. Walsh, MD, MPH Division of General Internal Medicine Women s Health
More informationSCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
More informationRole of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D.
Role of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D. Lung Cancer 219,440 new cases/year in U.S. (2009) 169,390 deaths/year in U.S. mortality greater than from breast, colon, prostate CA combined
More informationPatient Decision Aid. Summary Guide for Clinicians. Clinician s Checklist
U.S. Department of Health & Human Services About Us Careers Contact Us Español FAQ Email Updates Effective Health Care Home / Decision Aids / Lung Cancer Screening Tools Patient Decision Aid Summary Guide
More informationNC I CCC. A Comprehensive Cancer Center Designated by the National Cancer Institute
NC I CCC A Comprehensive Cancer Center Designated by the National Cancer Institute The Controversy About Lung Cancer Screening David S. Ettinger, M.D., FACP, FCCP Alex Grass Professor of Oncology The Sidney
More informationLung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer
Lung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer Doug Arenberg, M.D. University of Michigan Disclosures Objec6ve Define patients who will benefit from screening for
More informationRecommendations on Screening for Lung Cancer 2016
Recommendations on Screening for Lung Cancer 2016 Canadian Task Force on Preventive Health Care (CTFPHC) Putting Prevention into Practice Canadian Task Force on Preventive Health Care Groupe d étude canadien
More informationOriginal Policy Date
MP 6.01.21 Screening for Lung Cancer Using CT Scanning Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationDisclosures. Cancer Screening for Women. Topics for today. But what about? What works? What doesn t? I have no conflicts of interest
Cancer Screening for Women Disclosures What works? What doesn t? I have no conflicts of interest Judith M.E. Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence University
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationLUNG CANCER SCREENING COVERAGE IN STATE MEDICAID PROGRAMS
LUNG CANCER SCREENING COVERAGE IN STATE MEDICAID PROGRAMS Overview Lung cancer is the leading cancer killer among both women and men. Early detection is critical to fighting lung cancer, and low-dose computed
More informationShared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs
Review Article Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs Lisa M. Lowenstein 1, Gary M. R. Deyter 1, Shawn
More informationLUNGS? YOU GET THESE YOUR GUIDE TO YEARLY LUNG CANCER SCREENING CHECKED REGULARLY. WHAT ABOUT YOUR. Think. Screen. Know.
YOU GET THESE CHECKED REGULARLY. WHAT ABOUT YOUR LUNGS? YOUR GUIDE TO YEARLY LUNG CANCER SCREENING WHAT YOU SHOULD KNOW BEFORE, DURING, AND AFTER Think. Screen. Know. Talk to your doctor. TABLE OF CONTENTS
More informationLung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15. Dr. Tunji Fatoye Dr.
Lung Cancer Screening: A review of the recommendations Friday, November 11th, 2016 from 11:45 to 12:15 Dr. Tunji Fatoye Dr. Alan Kaplan Conflict of Interest Disclosure: Speaker Name: Alan Kaplan FINANCIAL
More informationLung cancer screening in Switzerland
SAMO Interdisciplinary Workshop on Chest Tumors 27 th and 28 th January 2017 Hotel Hermitage, Lucerne Lung cancer screening in Switzerland Walter Weder, MD, Professor of Surgery University Hospital Zurich,
More information